ImmuPharma plc (LON:IMM – Get Free Report) traded up 29.3% during trading on Thursday . The company traded as high as GBX 2.80 ($0.04) and last traded at GBX 2.78 ($0.04). 504,310 shares traded hands during mid-day trading, a decline of 95% from the average session volume of 10,802,349 shares. The stock had previously closed at GBX 2.15 ($0.03).
ImmuPharma Price Performance
The stock has a market cap of £11.37 million, a PE ratio of -4.62 and a beta of 1.53. The company’s fifty day moving average is GBX 3.46 and its 200-day moving average is GBX 2.52.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Robinhood Strategies Could Be a Game-Changer for Young Investors
- What Makes a Stock a Good Dividend Stock?
- Are These 3 Retail Stocks Oversold or Really in Trouble?
- 5 discounted opportunities for dividend growth investors
- IONQ & RGTI Join DARPA Quantum Initiative: High Stakes Are Ahead
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
